The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
A RESPONSE to ruxolitinib: update on 4-year trial follow-up
Jean-Jacques Kiladjian • 2 Mar 2018
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.